Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Psychiatry/Opioid Use

Opioid Use

29

Pipeline Programs↗

134

Active Trials↗

24

Companies Involved↗

Opioid Use is an emerging landscape with 29 programs across 24 companies. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

75/100

Mech. Concentration

14/100

Completion Rate

76/100

Attrition Rate

9/100

Pipeline

Programs by Phase

Preclinical5

BXCL501

BioXcel Therapeutics Inc

Methadone Dose

National Institute on Drug Abuse (NIDA)

Buprenorphine or Methadone Treatment

Indiana University

Dual NRT

Massachusetts General Hospital

Opioid Free Anaesthesia

Medical University of Lodz

Phase 19

Methadone Hydrochloride

National Institute of Allergy and Infectious Diseases (NIAID)

Mcam

The University of Texas Health Science Center at San Antonio

Drug a (blinded Drug)

University of Maryland, Baltimore

Drug B (blinded Drug)

University of Maryland, Baltimore

Drug C (blinded Drug)

University of Maryland, Baltimore

Phase 29

Psilocybin

COMPASS Pathways

Semaglutide

Novo Nordisk

Lemborexant

Eisai

Semaglutide Pen Injector

Universitaire Ziekenhuizen KU Leuven

Buspirone

Bristol-Myers Squibb

Phase 36

Naltrexone

Teva

Suvorexant

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Buprenorphine/naloxone

Astellas

Extended-Release Buprenorphine

Brigham and Women's Hospital

Patient-Oriented Dosing (POD)

Erin Winstanley

Approved

No programs

Analysis

Modality Breakdown

91%

Small molecule

21 of 23 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 79% of 29 pipeline programs.

Analysis

Trial Status

254

clinical trials

Recruiting89 · 35%

Completed87 · 34%

Not yet recruiting24 · 9%

Active, not recruiting18 · 7%

Withdrawn13 · 5%

Terminated11 · 4%

Other12 · 5%

Clinical Trials

Trial Activity

254 trials

Evaluation of the Safety and Effects of Psychoactive Substances in People With Past Opioid Use

Recruiting·—·Phase 1·NCT07218549·72 enrolled

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study With a Separate Open-label Cohort to Evaluate the Efficacy and Safety of Brenipatide as Adjunctive Treatment to Transmucosal Buprenorphine With or Without Naloxone in Early Recovery of Participants With Opioid Use Disorder (RENEW-Op-1)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07420283·465 enrolled

Facebook Intervention for Preventing Opioid Relapse Among American Indian Women: Wiidookaage'Win Pilot Preparatory Study (Aim 2)

Recruiting·MMayo Clinic·Preclinical·NCT05995886·60 enrolled

Nonopioid Pain Control Regimen After Open Reduction and Internal Fixation of Traumatic Fractures

Recruiting·HHenry Ford Health System·Approved·NCT06113211·75 enrolled

Ketamine for the Treatment of Opioid Use Disorder

Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT06943859·50 enrolled

A Dose-Finding Study of Methadone Loading Dose Initiation for Opioid Use Disorder With Fentanyl Use

Recruiting·UUniversity of Pennsylvania·Phase 1·NCT06877858·24 enrolled

Expanding Medication-Assisted Therapies in Central Asia

Recruiting·YYale University·Preclinical·NCT05579470·900 enrolled

Semaglutide for the Treatment of Opioid Use Disorder: A Pilot Randomized Controlled Trial

Recruiting·BBrigham and Women's Hospital·Phase 2·NCT06639464·46 enrolled

Supporting Treatment Access and Recovery in Co-Occurring Opioid Use and Mental Health Disorders

Recruiting·UUniversity of Massachusetts, Worcester·Preclinical·NCT05138614·1,000 enrolled

Integrating MOUD in Nonmedical Community Settings (Better Together)

Recruiting·Howard University·Preclinical·NCT06416020·400 enrolled

Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic: A Pilot Study

Recruiting·YYale University·Approved·NCT07176351·60 enrolled

Empowering Support Persons to Enhance the Recovery Capital of Postpartum Women With Opioid Use Disorder - R61 Phase

Recruiting·FFriends Research Institute, Inc.·Preclinical·NCT07787039·10 enrolled

The Effect of Light Intervention on Recovery in Individuals With Opioid Use Disorder (OUD)

Recruiting·UUniversity of Alabama at Birmingham·Preclinical·NCT06832007·105 enrolled

Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder

Recruiting·YYale University·Phase 1·NCT07800520·110 enrolled

Implementation and Effectiveness of A Bundled Intervention to End Opioid Overdoses by Increasing Treatment Uptake Post Discharge

Recruiting·UUniversity of Alabama at Birmingham·Approved·NCT07485335·160 enrolled

Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)